# A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

> **NCT04401761** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3189 (actual)

## Conditions studied

- Coronary Artery Disease
- Peripheral Artery Disease

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939, Xarelto)
- **DRUG:** Acetylsalicylic acid

## Key facts

- **NCT ID:** NCT04401761
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-09-29
- **Target enrollment:** 3189 (ACTUAL)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401761, "A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04401761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*